112 related articles for article (PubMed ID: 30656346)
1. Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist.
Compton BJ; Farrand KJ; Tang CW; Osmond TL; Speir M; Authier-Hall A; Wang J; Ferguson PM; Chan STS; Anderson RJ; Cooney TR; Hayman CM; Williams GM; Brimble MA; Brooks CR; Yong LK; Metelitsa LS; Zajonc DM; Godfrey DI; Gasser O; Weinkove R; Painter GF; Hermans IF
Org Biomol Chem; 2019 Jan; 17(5):1225-1237. PubMed ID: 30656346
[TBL] [Abstract][Full Text] [Related]
2. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
[TBL] [Abstract][Full Text] [Related]
3. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
[TBL] [Abstract][Full Text] [Related]
4. Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma.
Grasso C; Field CS; Tang CW; Ferguson PM; J Compton B; Anderson RJ; Painter GF; Weinkove R; F Hermans I; Berridge MV
Immunotherapy; 2020 Apr; 12(6):395-406. PubMed ID: 32316797
[No Abstract] [Full Text] [Related]
5. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
[TBL] [Abstract][Full Text] [Related]
6. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P
J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288
[TBL] [Abstract][Full Text] [Related]
7. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
8. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
9. Harnessing CD1d-restricted T cells toward antitumor immunity in humans.
Neparidze N; Dhodapkar MV
Ann N Y Acad Sci; 2009 Sep; 1174():61-7. PubMed ID: 19769737
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.
Shimizu K; Mizuno T; Shinga J; Asakura M; Kakimi K; Ishii Y; Masuda K; Maeda T; Sugahara H; Sato Y; Matsushita H; Nishida K; Hanada K; Dorrie J; Schaft N; Bickham K; Koike H; Ando T; Nagai R; Fujii S
Cancer Res; 2013 Jan; 73(1):62-73. PubMed ID: 23108144
[TBL] [Abstract][Full Text] [Related]
11. Species-specific activity of glycolipid ligands for invariant NKT cells.
Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy.
Thapa P; Zhang G; Xia C; Gelbard A; Overwijk WW; Liu C; Hwu P; Chang DZ; Courtney A; Sastry JK; Wang PG; Li C; Zhou D
Vaccine; 2009 May; 27(25-26):3484-8. PubMed ID: 19200815
[TBL] [Abstract][Full Text] [Related]
13. In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide.
Fernandez CS; Jegaskanda S; Godfrey DI; Kent SJ
Clin Exp Immunol; 2013 Sep; 173(3):480-92. PubMed ID: 23656283
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
15. NKT-cell glycolipid agonist as adjuvant in synthetic vaccine.
Liu Z; Guo J
Carbohydr Res; 2017 Nov; 452():78-90. PubMed ID: 29080431
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
[TBL] [Abstract][Full Text] [Related]
17. Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses.
Webb TJ; Carey GB; East JE; Sun W; Bollino DR; Kimball AS; Brutkiewicz RR
Pathog Dis; 2016 Aug; 74(6):. PubMed ID: 27297969
[TBL] [Abstract][Full Text] [Related]
18. Differential Role of Cathepsins S and B In Hepatic APC-Mediated NKT Cell Activation and Cytokine Secretion.
de Mingo Pulido Á; de Gregorio E; Chandra S; Colell A; Morales A; Kronenberg M; Marí M
Front Immunol; 2018; 9():391. PubMed ID: 29541077
[TBL] [Abstract][Full Text] [Related]
19. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
Mattarollo SR; Steegh K; Li M; Duret H; Foong Ngiow S; Smyth MJ
Immunol Cell Biol; 2013 Jan; 91(1):105-14. PubMed ID: 23090488
[TBL] [Abstract][Full Text] [Related]
20. Harnessing invariant NKT cells in vaccination strategies.
Cerundolo V; Silk JD; Masri SH; Salio M
Nat Rev Immunol; 2009 Jan; 9(1):28-38. PubMed ID: 19079136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
